Imperial College London
Portrait Picture

ProfessorBobBrown

Faculty of Medicine, Department of Surgery & Cancer

Senior Research Investigator
 
 
 
//

Contact

 

+44 (0)20 7594 1804b.brown Website

 
 
//

Assistant

 

Ms Sophie Lions +44 (0)20 7594 2792

 
//

Location

 

1 007Institute of Reproductive and Developmental BiologyHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Flower:2017:10.2174/1568009617666170206105131,
author = {Flower, KJ and Ghaem-Maghami, S and Brown, R},
doi = {10.2174/1568009617666170206105131},
journal = {Current Cancer Drug Targets},
title = {Is there a role for epigenetic enhancement of immunomodulatory approaches to cancer treatment?},
url = {http://dx.doi.org/10.2174/1568009617666170206105131},
volume = {17},
year = {2017}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - The efficacy of cancer immunotherapy relies on the ability of the host immune system to recognise the cancer as non-self and eliminate it from the body. Whilst this is an extremely fertile area of medical research, with positive clinical trials showing durable responses, attention must be paid to the subset of patients that do not respond to these treatments. Immune surveillance and immunoediting by the host could itself select for immune-evasive tumour cells during tumour development leading to immunotherapy resistance. One such mechanism of non-efficacy or resistance is the epigenetic silencing of a specific gene required in the immunotherapy response pathway. Epigenetics is the study of the control of expression patterns in a cell via mechanisms not involving a change in DNA sequence. All tumour types show aberrant epigenetic regulation of genes involved in all the hallmarks of cancer, including immunomodulation. Inhibition of key enzymes involved in maintenance of epigenetic states is another important area of research for new treatment strategies for cancer. Could epigenetic therapies be used to successfully enhance the action of immunomodulatory agents in cancer, and are they acting in the way we imagine? An understanding of the effects of epigenetic therapies on immunological pathways in both the tumour and host cells, especially the tumour microenvironment, will be essential to further develop such combination approaches.
AU  - Flower,KJ
AU  - Ghaem-Maghami,S
AU  - Brown,R
DO  - 10.2174/1568009617666170206105131
PY  - 2017///
SN  - 1873-5576
TI  - Is there a role for epigenetic enhancement of immunomodulatory approaches to cancer treatment?
T2  - Current Cancer Drug Targets
UR  - http://dx.doi.org/10.2174/1568009617666170206105131
UR  - http://www.ncbi.nlm.nih.gov/pubmed/28176650
UR  - http://hdl.handle.net/10044/1/45549
VL  - 17
ER  -
Download